ASTX660

SKU: orb1296257

Description

Tolinapant (ASTX660) is an orally active small molecule antagonist of cIAP1/2 and XIAP. It promotes immunogenic cell death (ICD) in sensitive head and neck squamous cell carcinoma (HNSCC) models in vitro, supporting its investigation in cancer immunotherapy and apoptosis research.

Research Area

Cell Biology

Images & Validation

−

Key Properties

−

CAS Number	1799328-86-1
MW	539.68
Purity	99.85% (May vary between batches)
Formula	C₃₀H₄₂FN₅O₃
SMILES	C[C@@H]1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc23)[C@@H](CN2CCOC[C@H]2C)CN1
Target	IAP,Apoptosis
Solubility	10% DMSO+40% PEG300+5% Tween-80+45% Saline:2 mg/mL (3.71 mM);DMSO:47 mg/mL (87.09 mM)

Bioactivity

−

In Vivo

METHODS: Tolinapant (ASTX660)(16 mg/kg, oral), XRT (single dose 8 Gy), or a combination of both treated a MEER syngeneic tumor xenograft mouse model. Tumors, spleens, and DLNs were harvested and analyzed for CD8 lymphocytes by flow cytometry. Tumor subpopulations were digested and T cells were magnetically selected and cocultured with inactivated dendritic cells presenting p15E peptide. Subsequent IFN-γ production was quantified using an ELISpot assay. RESULTS The number of CD8+ T cells in the spleen was significantly increased in animals treated with ASTX660 alone and in the subpopulation of animals treated with radiation ± ASTX660 (Figure 3(b)). In the draining lymph nodes of animals treated with XRT alone There was a significant increase in the number of CD8 T lymphocytes and an almost significant increase in the number of CD8 T lymphocytes in animals that received the combination treatment.

In Vitro

METHODS: Four human HNSCC cell lines (3 HPV-, 1 HPV+) were treated with IFN-γ (positive control, 10 ng/mL), TNFα (20 ng/mL), Tolinapant (ASTX660) (500 nM, 1 μM), and ASTX660 (250 nM, 500 nM, 1 μM) + TNFα for 48 hours, and then the intracellular APM components were analyzed by flow cytometry. RESULTS In all four cell lines, HLA-A, B, and C expression was consistently increased under ASTX660 + TNFα treatment. ASTX660 + TNFα may enhance tumor cell killing. METHODS: DLD1, HCT116, and SW48 were treated with ASTX660 (0.04, 0.2, 1 μM, 24 hours). After washing and cell lysis, western blot analysis was performed using antibodies specific for the indicated proteins. RESULTS ASTX660 concentrations as low as 40 nM were sufficient to rapidly reduce cIAP2 (but not cIAP1) levels.

Storage & Handling

−

Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

XIAP, inhibit, Inhibitor, IAP, ASTX 660, ASTX660, ASTX-660, cIAP

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

118169620 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

ASTX660 (orb1296257)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

CAS Number:	1799328-50-9
MW:	612.61
Formula:	C₃₀H₄₄Cl₂FN₅O₃

ASTX660

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

Tolinapant dihydrochloride [orb2815578]

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

ASTX660 (orb1296257)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors